Cardiovascular Drugs Practice Questions

Q: What is the mechanism of action of fibrates in the treatment of hyperlipidemia?

Activator of lipoprotein lipase. **Explanation:** Fibrates (e.g., Fenofibrate, Gemfibrozil) are the primary class of drugs used for treating **hypertriglyceridemia**. Their primary mechanism of action involves the activation of **Lipoprotein Lipase (LPL)**, the enzyme responsible for the hydrolysis of triglycerides in VLDL and chylomicrons. **Why Option A is correct:** Fibrates act as ligands for the **PPAR-α (Peroxisome Proliferator-Activated Receptor-alpha)** transcription factor. Activation of PPAR-α leads to increased expression of the LPL gene and a decrease in **ApoC-III** (an inhibitor of LPL). This dual action significantly enhances LPL activity, leading to rapid clearance of triglyceride-rich lipoproteins from the plasma. **Analysis of other options:** * **Option B (PPAR alpha agonist):** While fibrates *are* PPAR-α agonists, this is the **molecular target**, not the final functional mechanism that lowers lipids. In many exams, if both are present, "Activation of LPL" is considered the definitive physiological result that explains the drug's effect. * **Option C (Decreased synthesis of VLDL):** Fibrates do decrease VLDL secretion by the liver, but this is a secondary effect compared to the massive increase in peripheral clearance via LPL. * **Option D (Inhibitor of CETP):** This describes the mechanism of drugs like **Anacetrapib** or **Torcetrapib**, which aim to increase HDL levels, not fibrates. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Fibrates are the DOC for severe hypertriglyceridemia (TG >500 mg/dL) to prevent **acute pancreatitis**. * **Side Effects:** Myopathy (risk increases when combined with statins) and gallstones (due to increased biliary cholesterol excretion). * **Contraindication:** Avoid in patients with severe renal or hepatic dysfunction.

Q: Which condition is typically associated with the use of decoction?

Atrial fibrillation with a high ventricular rate. The question refers to **Digoxin** (often historically or colloquially linked to digitalis decoctions). Digoxin is a cardiac glycoside primarily used for its positive inotropic and negative chronotropic effects. **Why Option C is Correct:** In **Atrial Fibrillation (AFib)**, the atria generate rapid, disorganized electrical impulses. Digoxin is a drug of choice for **rate control** in AFib because it increases vagal tone (parasympathomimetic effect) [1], which slows conduction through the **Atrioventricular (AV) node**. This increases the refractory period of the AV node, effectively reducing the number of impulses reaching the ventricles and lowering the heart rate [1]. **Why Other Options are Incorrect:** * **A. Hypertrophic Obstructive Cardiomyopathy (HOCM):** Digoxin is **contraindicated** here. Its positive inotropic effect increases myocardial contractility, which can worsen the outflow tract obstruction and increase the pressure gradient across the subaortic area. * **B. High Output Failure:** This condition (caused by anemia, thyrotoxicosis, or Beriberi) is due to increased metabolic demand rather than primary pump failure. Digoxin is generally ineffective because the underlying pathology is not a deficit in contractility. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Inhibits Na+/K+ ATPase pump $\rightarrow$ increases intracellular Na+ $\rightarrow$ decreases Na+/Ca2+ exchange $\rightarrow$ increases intracellular Ca2+ (Inotropy). * **ECG Changes:** Characterized by the "reverse tick" sign or **Sagging ST-segment depression** [1]. * **Toxicity:** Hypokalemia predisposes to digoxin toxicity. The most common arrhythmia in toxicity is **Atrial Tachycardia with AV block**, while the most specific is **Bidirectional Ventricular Tachycardia** [1]. * **Antidote:** Digibind (Digoxin-specific antibody fragments).

Q: Which of the following is not a positive ionotropic agent?

Diltiazem. **Explanation:** The term **positive inotrope** refers to agents that increase the force of myocardial contraction. The correct answer is **Diltiazem** because it is a **negative inotrope**. **1. Why Diltiazem is the correct answer:** Diltiazem is a non-dihydropyridine **Calcium Channel Blocker (CCB)**. It works by blocking L-type calcium channels in the myocardium and cardiac conduction tissue. Since intracellular calcium is essential for the actin-myosin cross-bridge formation, blocking these channels reduces the force of contraction (negative inotropy). It is primarily used for rate control in atrial fibrillation and for hypertension. **2. Analysis of incorrect options:** * **Dobutamine:** A selective **$\beta_1$ agonist**. It increases cAMP levels in cardiac myocytes, leading to increased calcium influx and strong positive inotropic effects. It is a drug of choice for cardiogenic shock. * **Dopamine:** At moderate doses (5–10 µg/kg/min), it stimulates **$\beta_1$ receptors**, increasing cardiac contractility. At higher doses, it also acts on $\alpha_1$ receptors to cause vasoconstriction. * **Amrinone (and Milrinone):** These are **Phosphodiesterase-3 (PDE-3) inhibitors**. They prevent the breakdown of cAMP in the heart, increasing contractility (inotropy) and causing vasodilation (lusitropy), often referred to as "Inodilators." **Clinical Pearls for NEET-PG:** * **Inodilators:** Milrinone and Amrinone (increase CO while decreasing afterload). * **Digitalis:** A positive inotrope that works by inhibiting the $Na^+/K^+$ ATPase pump, indirectly increasing intracellular calcium. * **Contraindication:** Non-dihydropyridine CCBs (Diltiazem, Verapamil) are generally avoided in patients with Systolic Heart Failure (HFrEF) due to their negative inotropic effects.

Q: Which vitamin is used in the treatment of hyperlipoproteinemia?

Niacin/Nicotinic acid. Explanation: **Correct Option: C (Niacin/Nicotinic acid)** Niacin (Vitamin B3) is a water-soluble vitamin that, when used in pharmacological doses (grams per day), acts as a potent lipid-lowering agent [1]. It inhibits the enzyme **hormone-sensitive lipase** in adipose tissue, reducing the breakdown of triglycerides into free fatty acids (FFAs). Since FFAs are the primary substrate for hepatic VLDL synthesis, Niacin effectively lowers VLDL and LDL levels [2]. Most importantly, it is the **most effective drug for increasing HDL levels** (by decreasing its fractional clearance). **Incorrect Options:** * **Vitamin B1 (Thiamine):** Primarily used to treat Beriberi and Wernicke-Korsakoff syndrome; it has no role in lipid metabolism. * **Vitamin B6 (Pyridoxine):** Used to prevent peripheral neuropathy (e.g., with Isoniazid therapy) and in sideroblastic anemia; it does not affect lipoprotein levels. * **Vitamin B12 (Cyanocobalamin):** Essential for DNA synthesis and neurological function; its deficiency leads to megaloblastic anemia and subacute combined degeneration of the spinal cord. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** The most common side effect is **cutaneous flushing** (mediated by Prostaglandin D2/E2). This can be prevented by pre-treating with **Aspirin**. * **Metabolic Concerns:** Niacin can cause **hyperuricemia** (precipitating gout) and **hyperglycemia** (use with caution in diabetics) [1]. It may also cause acanthosis nigricans. * **Drug of Choice:** While statins are first-line for LDL reduction, Niacin is historically significant for patients with low HDL or elevated Lipoprotein(a) [2].

Q: Which lipid-lowering drug significantly reduces lipoprotein–a levels?

Nicotinic acid. **Explanation:** **Correct Answer: D. Nicotinic acid (Niacin)** Nicotinic acid is the most effective conventional lipid-lowering agent for reducing **Lipoprotein(a) [Lp(a)]** levels, typically achieving a reduction of 20–30%. It works by inhibiting the hepatic synthesis of apolipoprotein(a), the key component of Lp(a). While newer agents like PCSK9 inhibitors also reduce Lp(a), Nicotinic acid remains the classic pharmacological answer for this specific effect in medical examinations. **Analysis of Incorrect Options:** * **A & B (Fibrates - Fenofibrate/Gemfibrozil):** These are PPAR-α agonists primarily used to lower triglycerides and increase HDL. They have no significant or consistent effect on Lp(a) levels. * **C (Statins - Rosuvastatin):** Statins are the first-line treatment for lowering LDL-C by inhibiting HMG-CoA reductase. Interestingly, statins do not lower Lp(a) and, in some patients, may even cause a slight paradoxical increase in its levels. **High-Yield Clinical Pearls for NEET-PG:** * **Lp(a) Significance:** It is an independent risk factor for atherosclerosis and aortic stenosis. It is structurally similar to plasminogen and can interfere with fibrinolysis. * **Niacin’s "Best" Profile:** It is the most potent drug for **increasing HDL** levels. * **Side Effects:** The most common side effect is **cutaneous flushing** (mediated by Prostaglandin $D_2$), which can be prevented by taking Aspirin 30 minutes prior. It can also cause hyperuricemia (gout) and hyperglycemia. * **Newer Agents:** PCSK9 inhibitors (e.g., Evolocumab) also significantly reduce Lp(a), but Niacin is the traditional drug of choice for this question.

Q: Which of the following drugs is not used for the management of acute pulmonary edema?

Phenylephrine. ### Explanation The primary goal in managing acute pulmonary edema (APE) is to reduce pulmonary venous pressure by improving cardiac output and decreasing preload and afterload. **Why Phenylephrine is the Correct Answer:** Phenylephrine is a **pure $\alpha_1$-adrenergic agonist**. It causes potent systemic vasoconstriction, which significantly increases systemic vascular resistance (SVR) and afterload. In a failing heart (the typical cause of APE), an increase in afterload further reduces stroke volume and increases back-pressure into the pulmonary circulation, potentially worsening the edema. Therefore, it is generally **contraindicated** in APE. **Analysis of Incorrect Options:** * **Dobutamine:** A potent $\beta_1$ agonist with some $\beta_2$ activity. It is an "inodilator" that increases cardiac contractility and reduces afterload, making it a first-line agent for cardiogenic pulmonary edema with low cardiac output. * **Dopamine:** At medium doses (5–10 µg/kg/min), it acts on $\beta_1$ receptors to increase contractility. It is used when APE is accompanied by hypotension. * **Norepinephrine:** While it has $\alpha_1$ effects, its strong $\beta_1$ inotropic effect helps maintain cardiac output in cases of APE associated with severe cardiogenic shock (SBP < 70 mmHg) where maintaining coronary perfusion pressure is critical. **NEET-PG High-Yield Pearls:** * **Mnemonic for APE Management:** **LMNOP** (L-Loop diuretics/Lasix, M-Morphine, N-Nitrates, O-Oxygen, P-Position/Positive pressure ventilation). * **Inotropes vs. Vasopressors:** In APE, we prefer drugs that increase contractility without excessively increasing afterload. * **Phenylephrine Use Case:** It is primarily used for "warm shock" (sepsis) or anesthesia-induced hypotension where the heart is healthy but peripheral resistance is low.

Q: What is the mechanism of action of trimetazidine?

Inhibiting mitochondrial LC3-KAT. **Explanation:** **Mechanism of Action (Correct Answer: D)** Trimetazidine is a metabolic modulator used in the management of chronic stable angina. Its primary mechanism involves the **selective inhibition of long-chain 3-ketoacyl-CoA thiolase (LC3-KAT)**, a key enzyme in the mitochondrial fatty acid $\beta$-oxidation pathway. By inhibiting fatty acid oxidation, the drug shifts myocardial metabolism toward **glucose oxidation**. Since glucose oxidation requires less oxygen per mole of ATP produced compared to fatty acid oxidation, the heart becomes more oxygen-efficient, protecting cardiomyocytes from ischemic injury without affecting heart rate or blood pressure. **Analysis of Incorrect Options:** * **A. Fatty acid synthase inhibitor:** This enzyme is involved in the *synthesis* of fatty acids in the cytosol, not their mitochondrial oxidation for energy. * **B. Na channel inhibitor:** This describes Class I antiarrhythmics (like Lidocaine) or Ranolazine (which inhibits the *late* inward sodium current). * **C. K channel opener:** This is the mechanism of drugs like **Nicorandil** (which also has nitrate-like properties) or Minoxidil. **NEET-PG High-Yield Pearls:** * **Classification:** Trimetazidine is classified as a "pFOX inhibitor" (Partial Fatty Acid Oxidation inhibitor). * **Hemodynamic Neutrality:** Unlike nitrates or beta-blockers, it does not alter heart rate, blood pressure, or coronary blood flow, making it an excellent add-on therapy. * **Side Effects:** A high-yield point for exams is that Trimetazidine can induce **Parkinsonian symptoms** (tremors, rigidity) and gait disturbances, especially in the elderly, due to its ability to cross the blood-brain barrier. It is contraindicated in Parkinson’s disease.

Question 1

What is the mechanism of action of fibrates in the treatment of hyperlipidemia?

Accepted Answer

Activator of lipoprotein lipase

Answer

PPAR alpha agonist

Answer

Decreased synthesis of VLDL

Answer

Inhibitor of CETP

Question 2

Which condition is typically associated with the use of decoction?

Accepted Answer

Atrial fibrillation with a high ventricular rate

Answer

Hypertrophic obstructive cardiomyopathy

Answer

High output failure

Answer

All of the above

Question 3

Which of the following is not a positive ionotropic agent?

Accepted Answer

Diltiazem

Answer

Dobutamine

Answer

Dopamine

Answer

Amrinone

Question 4

Which vitamin is used in the treatment of hyperlipoproteinemia?

Accepted Answer

Niacin/Nicotinic acid

Answer

Vitamin B1

Answer

Vitamin B6

Answer

Vitamin B12

Question 5

A 65-year-old male had a myocardial infarction one year ago. The same patient now presents with hypertension. Which of the following drugs is best suited for this patient?

Accepted Answer

Lisinopril

Answer

Clonidine

Answer

Thiazide

Answer

Propranolol

Question 6

Which lipid-lowering drug significantly reduces lipoprotein–a levels?

Accepted Answer

Nicotinic acid

Answer

Fenofibrate

Answer

Gemfibrosil

Answer

Rosuvastatin

Question 7

Which of the following drugs is not used for the management of acute pulmonary edema?

Accepted Answer

Phenylephrine

Answer

Norepinephrine

Answer

Dopamine

Answer

Dobutamine

Question 8

It is essential to give a beta-blocker or Digoxin to increase the refractoriness of the AV node (AVN) prior to administration of which of the following for the treatment of atrial fibrillation?

Accepted Answer

All of the above

Answer

Quinidine

Answer

Flecainide

Answer

Moricizine

Question 9

What is the mechanism of action of trimetazidine?

Accepted Answer

Inhibiting mitochondrial LC3-KAT

Answer

Fatty acid synthase inhibitor

Answer

Na channel inhibitor

Answer

K channel opener

Question 10

Which of the following PDE-5 inhibitors has no significant interaction with high-fat meal intake?

Accepted Answer

Tadalafil

Answer

Sildenafil

Answer

Vardenafil

Answer

All of the above

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?